Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Hasılat
1,506
1,946
2,010
2,120
1,257
416
Hasılat Artışı (YoY)
-30%
-3%
-5%
69%
202%
136%
Satınalma Maliyeti
950
939
1,017
1,031
688
199
Brüt Kâr
556
1,007
993
1,089
569
216
Satış, Genel ve İdari
465
795
831
1,162
669
230
Araştırma ve Geliştirme
102
165
227
--
--
--
İşletme Giderleri
782
1,289
1,112
1,364
806
268
Diğer Finansman Gelirleri (Giderleri)
0
0
-3
-10
-5
--
Kâr Öncesi Gelir
-1,258
-70
-797
-34
-213
-54
Kira Vergisi Gideri
4
23
-8
53
15
-5
Net Kâr
-683
-5
-1,172
-832
-227
-48
Net Income Growth
Kâr Artışı
-45%
-100%
41%
267%
373%
-23%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
70.57
70.57
70.57
64.34
57.26
43.85
Hisse Değişimi (Yıllık Üst Üste)
0%
0%
10%
12%
31%
4%
EPS (Diluted)
-9.67
-0.07
-16.61
-12.94
-3.97
-1.09
EPS Artışı
-45%
-100%
28%
225.99%
262%
-25%
Öz sermaye akışı
159
72
-112
-799
-676
-213
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
36.91%
51.74%
49.4%
51.36%
45.26%
51.92%
Faaliyet Kâr Marjı
-15%
-14.49%
-5.92%
-12.92%
-18.77%
-12.25%
Kâr Marjı
-45.35%
-0.25%
-58.3%
-39.24%
-18.05%
-11.53%
Özsermaye Karlılık Oranı
10.55%
3.69%
-5.57%
-37.68%
-53.77%
-51.2%
EBITDA
983
196
1,810
666
-45
1
EBITDA Marjinali
65.27%
10.07%
90.04%
31.41%
-3.57%
0.24%
D&A EBITDA için
1,209
478
1,929
940
191
52
Faaliyet Kârı
-226
-282
-119
-274
-236
-51
Faaliyet Kâr Marjı
-15%
-14.49%
-5.92%
-12.92%
-18.77%
-12.25%
Verilen Vergi Oranı
-0.31%
-32.85%
1%
-155.88%
-7.04%
9.25%
Önemli İstatistikler
Önceki Kapanış
$1.98
Açılış fiyatı
$1.98
Günün Aralığı
$1.98 - $1.98
52 haftalık aralık
$1.88 - $4.21
İşlem hacmi
200
Ort.Hacim
308
EPS (TTM)
-1.98
Dividend yield
--
Piyasa Değeri
$136.7M
BICO GROUP AB nedir?
BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 586 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.